Projects funded by the NCN


Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

20 projects found matching your search criteria :

  1. DNA repair pathways contributing to resistance to photodynamic therapy and as possible theraupeutic targets

    Call: OPUS 8 , Panel: NZ5

    Principal investigator: dr hab. Elżbieta Speina

    Instytut Biochemii i Biofizyki Polskiej Akademii Nauk

  2. Role of the selected anti-tumor agents transported by electropermeabilization to the drug-sensitive and drug-resistant c...

    Call: PRELUDIUM 8 , Panel: NZ7

    Principal investigator: dr Joanna Barbara Weżgowiec

    Politechnika Wrocławska, Wydział Podstawowych Problemów Techniki

  3. Immunological biomarkers of drug resistant epilepsy and response to immunomodulatory therapy with ACTH in children

    Call: PRELUDIUM 6 , Panel: NZ4

    Principal investigator: Magdalena Dorota Kaczorowska-Frontczak

    Instytut "Pomnik - Centrum Zdrowia Dziecka"

  4. The role of EZH2 activity in the development of resistance to targeted therapy in melanoma

    Call: OPUS 28 , Panel: NZ7

    Principal investigator: dr Michał Jerzy Woźniak

    Uniwersytet Medyczny w Łodzi

  5. "One step to game changer": combined antimicrobial therapy based on AI and nanotechnology to combat challenging diabetes...

    Call: SONATA 19 , Panel: NZ7

    Principal investigator: dr Barbara Ewa Pucelik

    Sieć Badawcza ŁUKASIEWICZ - Krakowski Instytut Technologiczny

  6. Extensive analysis of the immunological profile of pediatric patients with acute lymphoblastic leukemia in order to iden...

    Call: PRELUDIUM 22 , Panel: NZ5

    Principal investigator: Anna Krętowska-Grunwald

    Uniwersytet Medyczny w Białymstoku

  7. Unlocking nature's potential - exploring the ability of newly isolated from the environment bacteriophage and its enzyme...

    Call: PRELUDIUM 22 , Panel: NZ9

    Principal investigator: Aleksandra Łukasiak

    Uniwersytet Gdański, Wydział Biologii

  8. Unveiling the molecular signature underlying resistance to CD19 CAR-T therapy in malignant cells.

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Marta Krawczyk

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego Polskiej Akademii Nauk

  9. The use of genetic analysis of liquid biopsy for predicting and monitoring ofresponse to therapies and tumor evolution i...

    Call: OPUS 22 , Panel: NZ7

    Principal investigator: dr Magdalena Olbryt

    Narodowy lnstytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy lnstytut Badawczy, Oddział w Gliwicach

  10. Inhibiting the Mitochondrial Intermembrane Space Assembly pathway as a newapproach to prevent metabolic reprogramming of...

    Call: OPUS 22 , Panel: NZ5

    Principal investigator: dr hab. Carlo Vascotto

    Międzynarodowy Instytut Mechanizmów i Maszyn Molekularnych Polskiej Akademii Nauk

  11. Development of phage-based tool with the potential to treat antibiotic-resistant gonorrhea

    Call: PRELUDIUM BIS 3 , Panel: NZ6

    Principal investigator: dr hab. Monika Julita Adamczyk-Popławska

    Uniwersytet Warszawski, Wydział Biologii

  12. RE-SENSE: Dual-loaded lipid nanoparticles to overcome the resistance of non-small cell lung cancer cells to personalized...

    Call: PRELUDIUM 20 , Panel: NZ7

    Principal investigator: Mikołaj Czajkowski

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  13. In search for molecular targets to overcome doxorubicin resistance in triple-negative breast cancer with the use of inno...

    Call: PRELUDIUM 20 , Panel: NZ7

    Principal investigator: Anna Karolina Pogorzelska

    Narodowy Instytut Leków

  14. FGF/FGFR-signalling in mediation of resistance to therapy in triple-positive breast cancer: clinical implications of PAM...

    Call: OPUS 20 , Panel: NZ4

    Principal investigator: dr hab. Hanna Maria Romańska-Knight

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  15. Dual CBR1-AKR1C3 inhibitors as a new approach to improve effectiveness and safety of anthracycline therapy.

    Call: PRELUDIUM 19 , Panel: NZ7

    Principal investigator: Marek Andrzej Jamrozik

    Uniwersytet Jagielloński, Collegium Medicum

  16. The significance of cancer specific PFK-II (PFKFB3 and PFKFB4) isoenzymes inhibition in overcoming resistance to BRAF in...

    Call: PRELUDIUM 16 , Panel: NZ5

    Principal investigator: Sonia Elżbieta Trojan

    Uniwersytet Jagielloński- Collegium Medicum, Collegium Medicum

  17. Role of RNA binding proteins in resistance to therapy of leukemia cells in bone marrow niche

    Call: HARMONIA 10 , Panel: NZ3

    Principal investigator: dr Paulina Podszywałow-Bartnicka

    Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polskiej Akademii Nauk

  18. Regulation of epithelial to mesenchymal transition and therapy resistance to antitumor therapies by MCPIP1

    Call: SONATA BIS 7 , Panel: NZ5

    Principal investigator: dr hab. Katarzyna Miękus

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  19. Molecular and pharmacological approaches based on inhibition of glycolysis to overcome de novo- and antiangiogenic thera...

    Call: OPUS 13 , Panel: NZ3

    Principal investigator: dr hab. Beata Teresa Pająk

    Wojskowy Instytut Higieny i Epidemiologii im. gen. Karola Kaczkowskiego

  20. Protein and gene expression analysis in the course of renal cancer stem-like cells' primary resistance to sorafenib in h...

    Call: PRELUDIUM 9 , Panel: NZ5

    Principal investigator: Zofia Felicja Bielecka

    Wojskowy Instytut Medyczny